Nightingale Health Oyj financials
Nightingale Health Oyj
743700WUIPC24LVMLO66 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €4.7M | €4.4M |
| Other income | €23.0K | €83.0K |
| Employee benefits expense | €8.6M | €8.8M |
| Operating profit (EBIT) | -€19.4M | -€18.6M |
| Net finance income / (cost) | €1.0M | €1.2M |
| Finance costs | €1.3M | €798.0K |
| Profit before tax | -€18.4M | -€17.4M |
| Income tax expense | €54.0K | €88.0K |
| Profit for the year | -€18.5M | -€17.5M |
| — attributable to owners | -€18.5M | -€17.5M |
| Total comprehensive income | -€18.4M | -€17.4M |
| Cash flow statement | ||
| Cash generated from operations | -€10.2M | -€8.1M |
| Net cash from operating activities | -€10.1M | -€8.4M |
| Income taxes paid | €46.0K | €107.0K |
| Net cash from investing activities | €9.5M | -€25.5M |
| Purchase of PP&E (capex) | €2.3M | €2.2M |
| Purchase of intangibles | €1.9M | €2.4M |
| Net cash from financing activities | -€1.6M | -€2.8M |
| Lease liability payments | €1.1M | €996.0K |
| Net change in cash | -€2.2M | -€36.8M |
| Balance sheet | ||
| Total assets | €74.5M | €90.8M |
| Non-current assets | €19.9M | €22.4M |
| Property, plant & equipment | €6.8M | €6.8M |
| Right-of-use assets | €3.3M | €1.8M |
| Intangible assets & goodwill | €1.0M | €1.0M |
| Current assets | €54.6M | €68.4M |
| Inventories | €1.7M | €704.0K |
| Trade & other receivables | €1.7M | €1.7M |
| Cash & equivalents | €41.3M | €43.7M |
| Total equity | €66.2M | €82.9M |
| Non-current liabilities | €2.1M | €1.0M |
| Long-term borrowings | €0 | €261.0K |
| Lease liabilities (non-current) | €2.1M | €724.0K |
| Current liabilities | €6.2M | €7.0M |
| Lease liabilities (current) | €1.2M | €1.1M |
| Deferred tax liabilities | €21.0K | €24.0K |
| Derived metrics | ||
| Free cash flow | -€12.4M | -€10.6M |
| Operating margin | -413.7% | -426.6% |
| Net margin | -393.4% | -400.7% |
| Return on equity | -27.9% | -21.1% |
| Cash conversion ratio | 0.55× | 0.48× |
| Capex coverage | -4.44× | -3.81× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€1.0M | -€154.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€150.0K | -€518.0K |
| Adjustments For Depreciation and Amortisation Expense | €8.3M | €8.2M |
| Adjustments For Finance Income Cost | €1.0M | €1.2M |
| Adjustments For Income Tax Expense | €72.0K | €88.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €197.0K | €56.0K |
| Adjustments For Sharebased Payments | €1.7M | €2.9M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€9.2M | -€7.5M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | -€37.0K |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €28.0K | €28.0K |
| Comprehensive Income Attributable To Owners of Parent | -€18.4M | -€17.4M |
| Current Advances | €827.0K | €1.0M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €261.0K | €566.0K |
| Current Investments | €9.9M | €22.4M |
| Current Tax Expense Income | €72.0K | €65.0K |
| Deferred Tax Assets | €21.0K | €7.0K |
| Deferred Tax Expense Income Recognised In Profit Or Loss | €19.0K | -€23.0K |
| Depreciation Amortisation and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €8.3M | €8.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€137.0K | -€218.0K |
| Equity and Liabilities | €74.5M | €90.8M |
| Finance Income | €2.3M | €2.0M |
| Increase Decrease Through Exercise of Options | €33.0K | — |
| Increase Decrease Through Sharebased Payment Transactions | €1.7M | €2.9M |
| Increase Decrease Through Transactions With Owners | €1.7M | €2.9M |
| Intangible Assets Other Than Goodwill | €8.3M | €12.3M |
| Interest Paid Classified As Operating Activities | €108.0K | €175.0K |
| Interest Received Classified As Investing Activities | €1.1M | €1.4M |
| Interest Received Classified As Operating Activities | €256.0K | €5.0K |
| Investments In Joint Ventures Accounted For Using Equity Method | €1.0K | €37.0K |
| Issued Capital | €80.0K | €80.0K |
| Liabilities | €8.3M | €8.0M |
| Other Adjustments To Reconcile Profit Loss | €156.0K | -€46.0K |
| Other Comprehensive Income | €21.0K | €56.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €21.0K | €56.0K |
| Other Expense By Nature | €6.1M | €4.6M |
| Other Noncurrent Assets | €469.0K | €432.0K |
| Proceeds From Exercise of Options | €33.0K | €0 |
| Repayments of Noncurrent Borrowings | €296.0K | €1.1M |
| Reserve of Exchange Differences On Translation | €167.0K | €146.0K |
| Retained Earnings | -€76.5M | -€59.7M |
| Share of Profit Loss of Joint Ventures Accounted For Using Equity Method | -€37.0K | -€31.0K |
Every line item above is a fact tagged in Nightingale Health Oyj's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.